ReviewKidney medicine
Advances in BK Virus Complications in Organ Transplantation and Beyond.
Review in Kidney medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 57 citations in OpenAlex.
- First-In-Human, Randomized, Placebo-Controlled, SAD and MAD Trial to Evaluate Safety, Tolerability, and PK/PD Modeling of Potravitug in Healthy Adults.Clinical and translational science · 2025Trial
- Single-cell profiling reveals epithelial and immune responses in BK polyomavirus-infected human kidney biopsies.JCI insight · 2026Article
- Kidney Transplant Recipients: Viral Infections and Malignancies.Pathogens (Basel, Switzerland) · 2026Observational
- BK polyomavirus in a Portuguese healthy group: seroprevalence, viral Excretion, and implications for transmission pathways.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Article
- It never rains but pours: disseminated nocardiosis in a renal transplant patient from Nigeria - a case report.BMC infectious diseases · 2025Article
- Long-Term Outcomes of BK Viremia in Kidney Transplant Recipients.Clinical transplantation · 2025Article
- Oncogenic Viruses in Organ Transplantation: Implications of Virus-Host Interactions for Cancer Development.Viruses · 2025Review
- Transplant failure in relation to BK viremia status among kidney transplant recipients in Jordan.Iranian journal of microbiology · 2025Article
- Immune Modulation by Microbiota and Its Possible Impact on Polyomavirus Infection.Pathogens (Basel, Switzerland) · 2025Review
- Pre-transplant tacrolimus fluctuations predict BK virus infection risk in kidney transplants.Clinical and experimental nephrology · 2025Article
- Surgical Complications After Kidney Transplantation.Annals of transplantation · 2025Article
- Donor HLA-DQ genetic and functional divergence affect the control of BK polyoma virus infection after kidney transplantation.Science advances · 2025Article
- Recent Insights into the Pathogenesis, Diagnostics, and Treatment of BK Virus Infections in Children After Hematopoietic Stem Cell Transplantation.Pathogens (Basel, Switzerland) · 2025Review
- The association between serum tacrolimus concentrations and BK viruria in kidney transplant recipients.Scientific reports · 2025Article
- BK Polyomavirus and acute kidney injury in transplant recipients: signaling pathways and molecular mechanisms.Virology journal · 2025Review
- Late BK Nephropathy 15 years post kidney transplant following chemotherapy: A case report.IDCases · 2025Article
- Suppression of large t antigen-stimulated CD4Frontiers in medicine · 2025Article
- Risk Prediction and Management of BKPyV-DNAemia in Kidney Transplant Recipients: A Multicenter Analysis of Immunosuppressive Strategies.Transplant international : official journal of the European Society for Organ Transplantation · 2025Article
- Applications of Biological Therapy for Latent Infections: Benefits and Risks.International journal of molecular sciences · 2024Review
- BK polyomavirus infection: more than 50 years and still a threat to kidney transplant recipients.Frontiers in transplantation · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 2 countries.
Funding
Abstract
Reactivation of BK virus (BKV) remains a dreaded complication in immunosuppressed states. Conventionally, BKV is known as a cause for BKV-associated nephropathy and allograft dysfunction in kidney transplant recipients. However, emerging studies have shown its negative impact on native kidney function and patient survival in other transplants and its potential role in diseases such as cancer. Because BKV-associated nephropathy is driven by immunosuppression, reduction in the latter is a convenient standard of care. However, this strategy is risk prone due to the development of donor-specific antibodies affecting long-term allograft survival. Despite its pathogenic role, there is a distinct lack of effective anti-BKV therapeutics. This limitation combined with increased morbidity and health care cost of BKV-associated diseases add to the complexity of BKV management. While summarizing recent advances in the pathogenesis of BKV-associated nephropathy and its reactivation in other organ transplants, this review illustrates the limitations of current and emerging therapeutic options and provides a compelling argument for an effective targeted anti-BKV drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.